Novartis gene therapy would be cost effective up to $900,000: U.S. group
(Reuters) – An experimental gene therapy for spinal muscular atrophy (SMA) developed by Swiss drugmaker Novartis AG would be worth a price of $310,000 to $900,000, according to an independent…